Pre-symptomatic diagnosis and treatment of filovirus diseases.
Filoviruses are virulent human pathogens which cause severe illness with high case fatality rates and for which there are no available FDA-approved vaccines or therapeutics. Diagnostic tools including antibody- and molecular-based assays, mass spectrometry, and next-generation sequencing are continually under development. Assays using the polymerase chain reaction (PCR) have become the mainstay for the detection of filoviruses in outbreak settings. In many cases, real-time reverse transcriptase-PCR allows for the detection of filoviruses to be carried out with minimal manipulation and equipment and can provide results in less than 2 h. In cases of novel, highly diverse filoviruses, random-primed pyrosequencing approaches have proved useful. Ideally, diagnostic tests would allow for diagnosis of filovirus infection as early as possible after infection, either before symptoms begin, in the event of a known exposure or epidemiologic outbreak, or post-symptomatically. If tests could provide an early definitive diagnosis, then this information may be used to inform the choice of possible therapeutics. Several exciting new candidate therapeutics have been described recently; molecules that have therapeutic activity when administered to animal models of infection several days post-exposure, once signs of disease have begun. The latest data for candidate nucleoside analogs, small interfering RNA (siRNA) molecules, phosphorodiamidate (PMO) molecules, as well as antibody and blood-product therapeutics and therapeutic vaccines are discussed. For filovirus researchers and government agencies interested in making treatments available for a nation's defense as well as its general public, having the right diagnostic tools to identify filovirus infections, as well as a panel of available therapeutics for treatment when needed, is a high priority. Additional research in both areas is required for ultimate success, but significant progress is being made to reach these goals.
Molecular and Translational Sciences Division, United States Army Medical Research Institute of Infectious Diseases Fort Detrick, MD, USA.
Amy C
AC
Shurtleff
Molecular and Translational Sciences Division, United States Army Medical Research Institute of Infectious Diseases Fort Detrick, MD, USA.
Chris A
CA
Whitehouse
Molecular and Translational Sciences Division, United States Army Medical Research Institute of Infectious Diseases Fort Detrick, MD, USA.
Michael D
MD
Ward
Molecular and Translational Sciences Division, United States Army Medical Research Institute of Infectious Diseases Fort Detrick, MD, USA.
Lisa H
LH
Cazares
Molecular and Translational Sciences Division, United States Army Medical Research Institute of Infectious Diseases Fort Detrick, MD, USA.
Sina
S
Bavari
Ebola; Marburg; diagnostics; therapeutics; zoonosis